105 related articles for article (PubMed ID: 24893120)
1. Affinity purification of recombinant human cytochrome P450s 3A4 and 1A2 using mixed micelle systems.
Ahn T; Bae CS; Yun CH
Protein Expr Purif; 2014 Sep; 101():37-41. PubMed ID: 24893120
[TBL] [Abstract][Full Text] [Related]
2. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli.
Vail RB; Homann MJ; Hanna I; Zaks A
J Ind Microbiol Biotechnol; 2005 Feb; 32(2):67-74. PubMed ID: 15739102
[TBL] [Abstract][Full Text] [Related]
3. Human cytochrome P450 expression in bacteria: Whole-cell high-throughput activity assay for CYP1A2, 2A6 and 3A4.
Esteves F; Campelo D; Urban P; Bozonnet S; Lautier T; Rueff J; Truan G; Kranendonk M
Biochem Pharmacol; 2018 Dec; 158():134-140. PubMed ID: 30308189
[TBL] [Abstract][Full Text] [Related]
4. Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.
Amaya GM; Durandis R; Bourgeois DS; Perkins JA; Abouda AA; Wines KJ; Mohamud M; Starks SA; Daniels RN; Jackson KD
Chem Res Toxicol; 2018 Jul; 31(7):570-584. PubMed ID: 29847931
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
6. 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2.
Arlt VM; Hewer A; Sorg BL; Schmeiser HH; Phillips DH; Stiborova M
Chem Res Toxicol; 2004 Aug; 17(8):1092-101. PubMed ID: 15310241
[TBL] [Abstract][Full Text] [Related]
7. Effects of histidine-tag on recombinant human cytochrome P450 3A5 catalytic activity in reconstitution systems.
Emoto C; Murayama N; Wakiya S; Yamazaki H
Drug Metab Lett; 2009 Dec; 3(4):207-11. PubMed ID: 19702542
[TBL] [Abstract][Full Text] [Related]
8. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
9. Expression of recombinant human cytochrome P450 1A2 in Escherichia coli bacterial mutagenicity tester strain.
Chun YJ
Arch Pharm Res; 1998 Jun; 21(3):305-9. PubMed ID: 9875448
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
[TBL] [Abstract][Full Text] [Related]
12. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
Shimada T; Gillam EM; Sutter TR; Strickland PT; Guengerich FP; Yamazaki H
Drug Metab Dispos; 1997 May; 25(5):617-22. PubMed ID: 9152602
[TBL] [Abstract][Full Text] [Related]
13. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol.
Badawi AF; Cavalieri EL; Rogan EG
Metabolism; 2001 Sep; 50(9):1001-3. PubMed ID: 11555828
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals.
Usmani KA; Cho TM; Rose RL; Hodgson E
Drug Metab Dispos; 2006 Sep; 34(9):1606-14. PubMed ID: 16790556
[TBL] [Abstract][Full Text] [Related]
15. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism.
Liu J; Ericksen SS; Sivaneri M; Besspiata D; Fisher CW; Szklarz GD
Arch Biochem Biophys; 2004 Apr; 424(1):33-43. PubMed ID: 15019834
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase.
Dong MS; Yamazaki H; Guo Z; Guengerich FP
Arch Biochem Biophys; 1996 Mar; 327(1):11-9. PubMed ID: 8615680
[TBL] [Abstract][Full Text] [Related]
17. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
18. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.
Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
Mutagenesis; 2005 Mar; 20(2):93-100. PubMed ID: 15728263
[TBL] [Abstract][Full Text] [Related]
19. Effects of enzyme sources on midazolam 1'-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase.
Emoto C; Murayama N; Yamazaki H
Drug Metab Lett; 2008 Aug; 2(3):190-2. PubMed ID: 19356092
[TBL] [Abstract][Full Text] [Related]
20. Effects of N-terminal modification of recombinant human cytochrome P450 1A2 on catalytic activity.
Kim HJ; Lee SB; Guengerich FP; Park YI; Dong MS
Xenobiotica; 2007 Apr; 37(4):356-65. PubMed ID: 17455110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
